Effect of Multiple Micronutrient Fortified Bread Consumption on Iron Deficiency Anemia in Women of Reproductive Age

October 25, 2021 updated by: Universidad Peruana Cayetano Heredia

Effect of Multiple Micronutrient Fortified Bread Consumption on Iron Deficiency Anemia in Women of Reproductive Age: A Randomized Controlled Trial

The project aims to assess if consuming two slices of multi-fortified bread daily for 120 days is effective in reducing iron deficiency anemia in women of reproductive age through a three-arm randomized trial.

Study Overview

Status

Recruiting

Detailed Description

Iron deficiency anemia (IDA) continues to be a public health priority in Peru and the world. The prevalence of the condition is high in women of reproductive age regardless of geographic area and socioeconomic status. Fortification of staple foods is recognized as a cost-effective strategy to reverse iron deficiency. In Peru, iron fortification of wheat flour and derived products is mandatory, but to date its effect on the IDA has not been evaluated. In recent years, evidence has been generated on the positive effect of zinc, vitamin A and vitamin B12 supplementation on hemoglobin (Hb) levels. This project is a three-arm randomized clinical trial that seeks to evaluate the effect of consuming two slices of bread fortified with a multivitamin premix (iron, folic acid, vitamin A, vitamin B12 and zinc) daily on iron deficiency anemia in non-pregnant women of reproductive age. As a control, one group will receive standard bread fortified according to Peruvian legislation and a third group will not receive treatment.

Study Type

Interventional

Enrollment (Anticipated)

351

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Tumbes, Peru
        • Recruiting
        • Centro de Salud Global
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Ferritin levels < 13 ng/ml,
  • Hemoglobin levels between 8 g/dL and 11.9 g/dL,
  • No plans to move during the duration of the study,
  • Commitment not to become pregnant during the duration of the study,
  • Signed informed consent.

Exclusion Criteria:

  • Pregnancy,
  • Amenorrhea not related to pregnancy,
  • Breastfeeding,
  • Chronic diseases (active TB, HIV, cancer, asthma, liver disease, coronary heart disease, chronic renal disease),
  • Hemoglobin levels < 8 g/dL,
  • Bleeding in the 3 months prior to recruitment,
  • Smoking,
  • Inability to sign informed consent,
  • Consumption of nutritional supplements.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MULTI-FORTIFIED
The product to be evaluated is bread made from wheat flour fortified according to Peruvian national standards [Riboflavin (0.18 mg), niacin (2.25 mg), thiamine (0.18 mg), folic acid (60ug), iron (4.2 mg)] and a previtamin mix [Vitamin A (240 ug), Vitamin b12 (0.72 ug), zinc (5.25 mg) per daily serving]. Participants will receive 2 slices of bread a day for 120 days. It is supplied by Panificadora Bimbo del Peru S.A.
Treatment with multifortified bread for 120 days
Active Comparator: FORTIFIED
The active comparator is bread fortified according to Peruvian national standards [Riboflavin (0.18 mg), niacin (2.25 mg), thiamine (0.18 mg), folic acid (60ug), iron (4.2 mg)]. Participants will receive 2 slices of bread a day for 120 days. It is supplied by Panificadora Bimbo del Peru S.A.
Treatment with standard bread, fortified according to current Peruvian guidelines for 120 days
No Intervention: CONTROL
The control group will be followed for 120 days. No product will be provided.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anemia
Time Frame: 120 days
Percentage of volunteers reaching normal Hb levels during the study.
120 days
Hemoglobin levels
Time Frame: 120 days
Variation in hemoglobin levels (mg/dL)
120 days
Serum ferritin levels
Time Frame: 120 days
Variation in serum ferritin levels (ug/l)
120 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hemoglobin levels
Time Frame: 90 days
Variation in hemoglobin levels (mg/dL)
90 days
Serum ferritin levels
Time Frame: 90 days
Variation in serum ferritin levels (ug/l)
90 days
Body iron content
Time Frame: 120 days
Variation in body iron content levels
120 days
Mean corpuscular volume
Time Frame: 120 days
Variation in mean corpuscular volume (fL)
120 days
Red Blood Cell Distribution Width
Time Frame: 120 days
Variation in Red Blood Cell Distribution Width (%)
120 days
Soluble transferrin receptor levels
Time Frame: 120 days
Variation in soluble transferrin receptor levels (nmol/L)
120 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 3, 2021

Primary Completion (Anticipated)

January 1, 2022

Study Completion (Anticipated)

February 1, 2022

Study Registration Dates

First Submitted

October 25, 2021

First Submitted That Met QC Criteria

October 25, 2021

First Posted (Actual)

November 2, 2021

Study Record Updates

Last Update Posted (Actual)

November 2, 2021

Last Update Submitted That Met QC Criteria

October 25, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Iron Deficiency Anemia

Clinical Trials on MULTI-FORTIFIED

Subscribe